BRAF and hyperplastic polyp: BRAF mutation is likely to be a convenient marker for the identification of a subset of CRCs with distinctive clinical, pathological and molecular features which may originate in hyperplastic polyps and serrated adenomas, while increases the risk of mortality in CRC patients by more than two-fold [95].